Sterling Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sterling Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-345	Closed	-$45.5K	–	3446
2025 Q1	$45.5K	Sell	345 -1,318	-79%	-$164K	﹤0.01%	1440
2024 Q4	$139K	Sell	1,663 -207	-11%	-$17K	﹤0.01%	1360
2024 Q3	$137K	Buy	+1,870	New	+$141K	﹤0.01%	1335
2015 Q4	–	Sell	-11,018	Closed	-$441K	–	1053
2015 Q3	$441K	Buy	+11,018	New	+$359K	﹤0.01%	793

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sterling Capital Management's ITCI Position: Q2 2025 in Review

Sterling Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 345 shares — an estimated $45.5K sold.

Sterling Capital Management first reported a position in ITCI in Q3 2015 and held it in 4 quarters. The position peaked at $441K in Q3 2015. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Sterling Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Sterling Capital Management sold 345 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $45.5K.
Sterling Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 4 quarters.
Sterling Capital Management's Intra-Cellular Therapies Inc. position peaked at $441K in Q3 2015.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.